Role of P-glycoprotein in the disposition of macrocyclic lactones: a comparison between ivermectin, eprinomectin, and moxidectin in mice

Drug Metabolism and Disposition

Volumn 38, Issue 4, 2010, Pages 573-580

  Kiki Mvouaka, Solange ^a   Ménez, Cécile ^a   Borin, Christiane ^a,c   Lyazrhi, Faouri ^b   Foucaud Vignault, Magali ^a   Dupuy, Jacques ^a   Collet, Xavier ^d   Alvinerie, Michel ^a   Lespine, Anne ^a  

^a CEMAGREF   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c Université de Toulouse III Ecole Nationale Supérieure de Formation de l'Enseignement Agricole   (France)

^d France   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPRINOMECTIN; GLYCOPROTEIN P; IVERMECTIN; MACROLIDE; MOXIDECTIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXCRETION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE PERFUSION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTHELMINTICS; AREA UNDER CURVE; BRAIN; FECES; INJECTIONS, INTRAVENOUS; INTESTINES; IVERMECTIN; MACROLIDES; MALE; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; PERFUSION; TISSUE DISTRIBUTION;

MUS;

EID: 77950236895     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.030700     Document Type: Article

References (41)

1. Alvinerie M, Dupuy J, Eeckhoutte C, Sutra JF, and Kerboeuf D (2001) In vitro metabolism of moxidectin in Haemonchus contortus adult stages. Parasitol Res 87:702-704.
2. Alvinerie M, Escudero E, Sutra JF, Eeckhoutte C, and Galtier P (1998) The pharmacokinetics of moxidectin after oral and subcutaneous administration to sheep. Vet Res 29:113-118.
3. Ballent M, Lifschitz A, Virkel G, Sallovitz J, and Lanusse C (2006) Modulation of the P-glycoprotein-mediated intestinal secretion of ivermectin: in vitro and in vivo assessments. Drug Metab Dispos 34:457-463.
4. Baoliang P, Yuwan W, Zhende P, Lifschitz AL, and Ming W (2006) Pharmacokinetics of eprinomectin in plasma and milk following subcutaneous administration to lactating dairy cattle. Vet Res Commun 30:263-270.
5. Bodo A, Bakos E, Szeri F, Varadi A, and Sarkadi B (2003) The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett 140-141:133-143.
6. Canadian Council on Animal Care (1984) Guide to the Care and Use of Experimental Animals. Canadian Council on Animal Care, Ottawa, ON, Canada.
7. Chen C, Liu X, and Smith BJ (2003) Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development. Curr Drug Metab 4:272-291.
8. Chiu SH, Taub R, Sestokas E, Lu AY, and Jacob TA (1987) Comparative in vivo and in vitro metabolism of ivermectin in steers, sheep, swine, and rat. Drug Metab Rev 18:289-302.
9. Cisternino S, Mercier C, Bourasset F, Roux F, and Scherrmann JM (2004) Expression, upregulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 64:3296-3301.
10. del Amo EM, Heikkinen AT, and Mönkkönen J (2009) In vitro-in vivo correlation in Pglycoprotein mediated transport in intestinal absorption. Eur J Pharm Sci 36:200-211.
11. Didier A and Loor F (1996) The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor. Anticancer Drugs 7:745-751.
12. Geyer J, Gavrilova O, and Petzinger E (2009) Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein- and bcrp-deficient knockout mice. J Vet Pharmacol Ther 32:87-96.
13. Griffin J, Fletcher N, Clemence R, Blanchflower S, and Brayden DJ (2005) Selamectin is a potent substrate and inhibitor of human and canine P-glycoprotein. J Vet Pharmacol Ther 28:257-265.
14. Hennessy DR and Alvinerie MR (2002) Pharmacokinetics of the macrocyclic lactones: conventional wisdom and new paradigms, in Macrocyclic Lactones and Antiparasitic Therapy (Vercruysse J and Rew RS eds) pp 97-123, CAB International, Wallingford, Oxfordshire, UK.
15. Juliano RL and Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162.
16. Kwei GY, Alvaro RF, Chen Q, Jenkins HJ, Hop CE, Keohane CA, Ly VT, Strauss JR, Wang RW, Wang Z, et al. (1999) Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab Dispos 27:581-587.
17. Lacombe O, Woodley J, Solleux C, Delbos JM, Boursier-Neyret C, and Houin G (2004) Localisation of drug permeability along the rat small intestine, using markers of the paracellular, transcellular and some transporter routes. Eur J Pharm Sci 23:385-391.
18. Laffont CM, Toutain PL, Alvinerie M, and Bousquet-Mélou A (2002) Intestinal secretion is a major route for parent ivermectin elimination in the rat. Drug Metab Dispos 30:626-630.
19. Lankas GR, Cartwright ME, and Umbenhauer D (1997) P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol Appl Pharmacol 143:357-365.
20. Lanusse C, Lifschitz A, Virkel G, Alvarez L, Sánchez S, Sutra JF, Galtier P, and Alvinerie M (1997) Comparative plasma disposition kinetics of ivermectin, moxidectin and doramectin in cattle. J Vet Pharmacol Ther 20:91-99.
21. Lespine A, Alvinerie M, Vercruysse J, Prichard RK, and Geldhof P (2008) ABC transporter modulation: a strategy to enhance the activity of macrocyclic lactone anthelmintics. Trends Parasitol 24:293-298.
22. Lespine A, Dupuy J, Orlowski S, Nagy T, Glavinas H, Krajcsi P, and Alvinerie M (2006) Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3). Chem Biol Interact 159:169-179.
23. Lespine A, Martin S, Dupuy J, Roulet A, Pineau T, Orlowski S, and Alvinerie M (2007) Interaction of macrocyclic lactones with P-glycoprotein: structure-affinity relationship. Eur J Pharm Sci 30:84-94.
24. Lifschitz A, Virkel G, Sallovitz J, Sutra JF, Galtier P, Alvinerie M, and Lanusse C (2000) Comparative distribution of ivermectin and doramectin to parasite location tissues in cattle. Vet Parasitol 87:327-338.
25. MacLean C, Moenning U, Reichel A, and Fricker G (2008) Closing the gaps: a full scan of the intestinal expression of p-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats. Drug Metab Dispos 36:1249-1254.
26. Muenster U, Grieshop B, Ickenroth K, and Gnoth MJ (2008) Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions. Pharm Res 25:2320-2326.
27. Perez M, Blazquez AG, Real R, Mendoza G, Prieto JG, Merino G, and Alvarez AI (2009) In vitro and in vivo interaction of moxidectin with BCRP/ABCG2. Chem Biol Interact 180:106-112.
28. Pouliot JF, L'Heureux F, Liu Z, Prichard RK, and Georges E (1997) Reversal of P-glycoproteinassociated multidrug resistance by ivermectin. Biochem Pharmacol 53:17-25.
29. Prichard RK and Roulet A (2007) ABC transporters and β-tubulin in macrocyclic lactone resistance: prospects for marker development. Parasitology 134:1123-1132.
30. Ranjan S, Wang GT, Hirschlein C, and Simkins KL (2002) Selection for resistance to macrocyclic lactones by Haemonchus contortus in sheep. Vet Parasitol 103:109-117.
31. Roulet A, Puel O, Gesta S, Lepage JF, Drag M, Soll M, Alvinerie M, and Pineau T (2003) MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur J Pharmacol 460:85-91.
32. Schinkel AH and Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3-29.
33. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, et al. (1997) Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94:4028-4033.
34. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, and te Riele HP (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
35. Schinkel AH, Wagenaar E, Mol CA, and van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524.
36. Seelig A and Landwojtowicz E (2000) Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci 12:31-40.
37. Stephens RH, Tanianis-Hughes J, Higgs NB, Humphrey M, and Warhurst G (2002) Regiondependent modulation of intestinal permeability by drug efflux transporters: in vitro studies in mdr1a(-/-) mouse intestine. J Pharmacol Exp Ther 303:1095-1101.
38. Sutra JF, Chartier C, Galtier P, and Alvinerie M (1998) Determination of eprinomectin in plasma by high-performance liquid chromatography with automated solid phase extraction and fluorescence detection. Analyst 123:1525-1527.
39. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, and Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
40. van der Velde AE, Vrins CL, van den Oever K, Kunne C, Oude Elferink RP, Kuipers F, and Groen AK (2007) Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice. Gastroenterology 133:967-975.
41. Varma MV and Panchagnula R (2005) pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs: kinetic analysis of quinidine efflux in situ. J Pharm Sci 94:2632-2643.